Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03129100 · ClinicalTrials.gov registry record · Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
A Phase 3 study of Axial Spondyloarthritis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 773
- Enrollment target
- 20
- Study locations
NCT03129100 is a Phase 3 study of Axial Spondyloarthritis that has completed, run by Eli Lilly and Company. The registered enrollment target is 773 participants, above the 301-participant average among 4 other Axial Spondyloarthritis trials with a reported enrollment target (157% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT03129100, a Phase 3 study of Axial Spondyloarthritis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 773 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ixekizumab
Study Locations (20)
California
- Care Access Research - Huntington Beach - Huntington Beach
- Desert Medical Advances - Palm Desert
Florida
- Arthritis Rheumatic Disease Specialties - Aventura
- Sarasota Arthritis Center - Sarasota
Maryland
- Klein and Associates MD, PA - Cumberland
- Klein and Associates MD, PA - Hagerstown
North Carolina
- Shanahan Rheumatology & Immunotherapy, PLLC - Raleigh
- Carolina Arthritis Associates - Wilmington
Arizona
- Arizona Arthritis & Rheumatology Research - Phoenix
Colorado
- Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC - Colorado Springs
Connecticut
- Clinical Research Center of CT/NY - Danbury
Georgia
- Marietta Rheumatology - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 773 participants |
| Start Date | 2017-05-09 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03129100
The ClinicalTrials.gov registry entry for NCT03129100 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 773 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 301-participant average among 4 other Axial Spondyloarthritis trials with a reported enrollment target (157% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Axial Spondyloarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03129100 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT03129100 about?
NCT03129100 is a clinical study titled "A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis". The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
What is the current status of trial NCT03129100?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 773 participants. The study started on 2017-05-09. Estimated completion is 2021-05-27.
What conditions does trial NCT03129100 study?
This clinical trial studies the following conditions: Axial Spondyloarthritis.
What interventions are being tested in trial NCT03129100?
The interventions under investigation include: Placebo (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT03129100?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03129100 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Axial Spondyloarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.